Fresenius Kabi’s denosumab biosimilar candidate shows positive clinical trial results

Fresenius Kabi announced today that its biosimilar candidate FKS518, a denosumab biosimilar candidate for the US reference product Prolia®*, successfully met its primary and secondary objectives in a recently conducted clinical trial on pharmacokinetic similarity. For more information, please see the website of Fresenius Kabi. *Prolia® is a registered trademark of Amgen Inc.

The release as fetched from its publisher. fresenius.com ↗